Emergent BioSolutions, a multinational biopharmaceutical company, has ended all activities related to its planned acquisition of Protein Sciences, a vaccine company.
Subscribe to our email newsletter
Emergent will pursue full repayment of the $10 million loan, which is secured by substantially all of Protein Sciences’s assets, and settlement of the outstanding litigation against Protein Sciences and its senior management initiated by Emergent in connection with an earlier executed asset purchase agreement.
Daniel Abdun-Nabi, president and COO of Emergent BioSolutions, said: “After protracted efforts to determine whether a mutually agreeable acquisition could be completed, we have concluded that such a transaction is no longer practical. In line with Emergent’s growth strategy, we are actively pursuing other opportunities which would complement our product pipeline.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.